↓ Skip to main content

Dove Medical Press

Article Metrics

How we make cell therapy in Italy

Overview of attention for article published in Drug Design, Development and Therapy, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

googleplus
1 Google+ user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
19 Mendeley
Title
How we make cell therapy in Italy
Published in
Drug Design, Development and Therapy, August 2015
DOI 10.2147/dddt.s80403
Pubmed ID
Authors

Rosaria Giordano, Tiziana Montemurro, Mariele Viganò, Silvia Budelli, Elisa Montelatici, Cristiana Lavazza, Luigi Marino, Valentina Parazzi, Lorenza Lazzari

Abstract

In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene therapy, and tissue engineered products, as a new class of drugs. Their manufacture requires the same pharmaceutical framework as for conventional drugs and this means that industrial, large-scale manufacturing process has to be adapted to the peculiar characteristics of cell-containing products. Our hospital took up the challenge of this new path in the early 2000s; and herein we describe the approach we followed to set up a pharmaceutical-grade facility in a public hospital context, with the aim to share the solutions we found to make cell therapy compliant with the requirements for the production and the quality control of a high-standard medicinal product.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 37%
Student > Master 3 16%
Student > Ph. D. Student 2 11%
Other 1 5%
Librarian 1 5%
Other 0 0%
Unknown 5 26%
Readers by discipline Count As %
Medicine and Dentistry 3 16%
Biochemistry, Genetics and Molecular Biology 2 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Economics, Econometrics and Finance 2 11%
Agricultural and Biological Sciences 1 5%
Other 2 11%
Unknown 7 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2015.
All research outputs
#5,491,813
of 9,726,436 outputs
Outputs from Drug Design, Development and Therapy
#459
of 1,145 outputs
Outputs of similar age
#125,969
of 236,250 outputs
Outputs of similar age from Drug Design, Development and Therapy
#56
of 147 outputs
Altmetric has tracked 9,726,436 research outputs across all sources so far. This one is in the 26th percentile – i.e., 26% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,145 research outputs from this source. They receive a mean Attention Score of 3.8. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,250 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.